BR112015022590A2 - nova composição farmacêutica para o tratamento de infecções fúngicas - Google Patents

nova composição farmacêutica para o tratamento de infecções fúngicas

Info

Publication number
BR112015022590A2
BR112015022590A2 BR112015022590A BR112015022590A BR112015022590A2 BR 112015022590 A2 BR112015022590 A2 BR 112015022590A2 BR 112015022590 A BR112015022590 A BR 112015022590A BR 112015022590 A BR112015022590 A BR 112015022590A BR 112015022590 A2 BR112015022590 A2 BR 112015022590A2
Authority
BR
Brazil
Prior art keywords
component
treatment
pharmaceutical composition
fungal infections
components
Prior art date
Application number
BR112015022590A
Other languages
English (en)
Other versions
BR112015022590B8 (pt
BR112015022590B1 (pt
Inventor
Karlsson Ewa
Kaufmann Peter
Feizollahi Ashkar Sahar
Original Assignee
Moberg Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015022590(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Moberg Pharma Ab filed Critical Moberg Pharma Ab
Publication of BR112015022590A2 publication Critical patent/BR112015022590A2/pt
Publication of BR112015022590B1 publication Critical patent/BR112015022590B1/pt
Publication of BR112015022590B8 publication Critical patent/BR112015022590B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

resumo nova composição farmacêutica para o tratamento de infecções fúngicas são fornecidas composições farmacêuticas adequadas para aplicação tópica para a unha para o tratamento de doenças da unha, tais como onicomicose, compreendendo um componente à base de ureia, um componente de diol, tal como propileno glicol, um componente de ácido orgânico, tal como ácido láctico, e um componente de triol, tal como glicerol. são fornecidos ainda métodos de melhorar a estabilidade de armazenamento de uma composição farmacêutica adequada para aplicação tópica à pele e/ou unhas que compreendem tais componentes à base de ureia, componentes de diol, componentes de ácidos orgânicos, e, opcionalmente, uma base aquosa, cujo método que compreende a adição de um componente de triol, tal como glicerol, para a composição antes do referido armazenamento.
BR112015022590A 2013-03-15 2014-02-28 Composição farmacêutica adequada para aplicação tópica à pele e/ou unhas, seu uso e método para melhorar a estabilidade de armazenamento de uma composição farmacêutica adequada para aplicação tópica à pele e/ou unhas BR112015022590B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2013/050654 WO2014140507A1 (en) 2013-03-15 2013-03-15 Pharmaceutical composition for the treatment of fungal infections
GBPCT/GB2013/050654 2013-03-15
PCT/GB2014/050604 WO2014140524A1 (en) 2013-03-15 2014-02-28 Pharmaceutical composition for the treatment of fungal infections

Publications (3)

Publication Number Publication Date
BR112015022590A2 true BR112015022590A2 (pt) 2017-07-18
BR112015022590B1 BR112015022590B1 (pt) 2020-08-25
BR112015022590B8 BR112015022590B8 (pt) 2023-03-21

Family

ID=48142011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022590A BR112015022590B8 (pt) 2013-03-15 2014-02-28 Composição farmacêutica adequada para aplicação tópica à pele e/ou unhas, seu uso e método para melhorar a estabilidade de armazenamento de uma composição farmacêutica adequada para aplicação tópica à pele e/ou unhas

Country Status (27)

Country Link
US (2) US8987330B2 (pt)
EP (1) EP2777689B1 (pt)
JP (1) JP6503303B2 (pt)
KR (1) KR101582448B1 (pt)
CN (2) CN109394743A (pt)
BR (1) BR112015022590B8 (pt)
CA (1) CA2883613C (pt)
CY (1) CY1116559T1 (pt)
DK (1) DK2777689T3 (pt)
ES (1) ES2543957T3 (pt)
HK (1) HK1208378A1 (pt)
HR (1) HRP20150823T1 (pt)
HU (1) HUE026887T2 (pt)
IL (1) IL241175B (pt)
ME (1) ME02199B (pt)
MX (1) MX2015012273A (pt)
MY (1) MY176291A (pt)
PH (1) PH12015502073B1 (pt)
PL (1) PL2777689T3 (pt)
PT (1) PT2777689E (pt)
RS (1) RS54131B1 (pt)
SA (1) SA515361162B1 (pt)
SG (1) SG11201505763QA (pt)
SI (1) SI2777689T1 (pt)
SM (1) SMT201500214B (pt)
WO (2) WO2014140507A1 (pt)
ZA (1) ZA201505343B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140507A1 (en) 2013-03-15 2014-09-18 Moberg Pharma Ab Pharmaceutical composition for the treatment of fungal infections
KR101599260B1 (ko) * 2015-07-30 2016-03-03 (주)우신메딕스 조갑진균증의 예방 또는 치료용 약학 조성물 및 이의 제조방법
ITUB20153759A1 (it) * 2015-09-21 2017-03-21 Federica Livieri Composizione antifungina ad uso topico per il trattamento dell'onicomicosi e relativo metodo
US10251858B1 (en) 2016-08-08 2019-04-09 Marlinz Pharma, LLC Composition for treating fungal infections in nails
US10543276B2 (en) 2016-08-08 2020-01-28 Marlinz Pharma, LLC Topical compositions
GB2554101B (en) * 2016-09-20 2021-05-05 Insense Ltd Composition for the treatment of a fungal infection
US20190151214A1 (en) * 2017-11-21 2019-05-23 Topix Pharmaceuticals, Inc. Methods and compositions for treatment of skin
KR20210107043A (ko) * 2018-12-19 2021-08-31 말린즈 파마 엘엘씨 국소 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296130A (en) 1979-08-30 1981-10-20 Herschler R J Methylsulfonylmethane and methods of use
US4672078A (en) 1985-07-03 1987-06-09 Schering-Plough Corporation Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations
US5525635A (en) 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
SE462139B (sv) * 1986-02-04 1990-05-14 Sven Moberg Farmaceutisk komposition, innehaallande propylenglykol och karbamid, foer behandling av bl.a. nagelsvamp och seborroiskt eksem
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
JP3820805B2 (ja) 1999-07-08 2006-09-13 株式会社ノエビア 皮膚外用剤
JP2003095914A (ja) * 2001-09-21 2003-04-03 Toyo Beauty Kk 尿素含有外用剤
US6986896B2 (en) * 2002-03-20 2006-01-17 Bradley Pharmaceuticals, Inc. Method of treating fungal conditions of the skin
US6573301B1 (en) * 2002-04-23 2003-06-03 Bradley Pharmaceuticals, Inc. Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
US8158138B1 (en) * 2004-05-20 2012-04-17 Fougera Pharmaceuticals, Inc. Urea compositions and their methods of manufacture
JP4972895B2 (ja) * 2005-08-29 2012-07-11 大正製薬株式会社 尿素配合外用製剤
US8435500B2 (en) 2005-11-01 2013-05-07 L'oréal Nail whitening composition
BR112012003209A2 (pt) 2009-08-13 2016-03-01 Moberg Derma Ab composições e métodos para tratar infecção fúngica da unha
WO2012110430A1 (en) * 2011-02-10 2012-08-23 Moberg Derma Ab Novel composition for topical use on a nail
WO2014140507A1 (en) 2013-03-15 2014-09-18 Moberg Pharma Ab Pharmaceutical composition for the treatment of fungal infections

Also Published As

Publication number Publication date
CN104661639B (zh) 2019-06-28
US20140275254A1 (en) 2014-09-18
HK1208378A1 (en) 2016-03-04
HRP20150823T1 (hr) 2015-09-11
HUE026887T2 (en) 2016-07-28
ES2543957T3 (es) 2015-08-26
KR20150054824A (ko) 2015-05-20
KR101582448B1 (ko) 2016-01-04
BR112015022590B8 (pt) 2023-03-21
ME02199B (me) 2016-02-20
PH12015502073A1 (en) 2016-01-25
JP2016514121A (ja) 2016-05-19
MX2015012273A (es) 2016-01-25
WO2014140524A1 (en) 2014-09-18
US20150306052A1 (en) 2015-10-29
SG11201505763QA (en) 2015-08-28
CN104661639A (zh) 2015-05-27
CY1116559T1 (el) 2017-03-15
WO2014140507A1 (en) 2014-09-18
SI2777689T1 (sl) 2015-08-31
CA2883613C (en) 2016-04-12
DK2777689T3 (da) 2015-06-22
CN109394743A (zh) 2019-03-01
ZA201505343B (en) 2017-06-28
US8987330B2 (en) 2015-03-24
IL241175B (en) 2019-10-31
US9782372B2 (en) 2017-10-10
RS54131B1 (en) 2015-12-31
IL241175A0 (en) 2015-11-30
JP6503303B2 (ja) 2019-04-17
SMT201500214B (it) 2015-10-30
CA2883613A1 (en) 2014-09-18
EP2777689B1 (en) 2015-05-27
PT2777689E (pt) 2015-09-11
EP2777689A1 (en) 2014-09-17
SA515361162B1 (ar) 2016-11-09
PH12015502073B1 (en) 2016-01-25
PL2777689T3 (pl) 2015-10-30
BR112015022590B1 (pt) 2020-08-25
MY176291A (en) 2020-07-27

Similar Documents

Publication Publication Date Title
BR112015022590A2 (pt) nova composição farmacêutica para o tratamento de infecções fúngicas
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
CO2017011851A2 (es) Compuestos novedosos
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
EA201890218A1 (ru) Ретиноидные композиции для местного применения
BR112017016019A2 (pt) método para tratamento de câncer, artigo para fabricação, e, kit.
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112017026294A2 (pt) formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição.
UY32502A (es) Agentes antihelmínticos y su utilización
CO7131352A2 (es) Composiciones farmacéuticas tópicas
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
UY35704A (es) Compuestos y composiciones como inhibidores de la mek
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
MY193312A (en) Topical formulation for promoting wound healing
DOP2016000007A (es) Pirazolpiridinas sustituidas
JP2016514121A5 (pt)
PH12018500910A1 (en) Novel method of use and compositions
BR112015014885A2 (pt) combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos.
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
ES2598753T3 (es) Composición farmacéutica para el tratamiento de la tendinitis calcificada y/o bursitis calcificada
PE20150755A1 (es) Formulacion transdermica que contiene inhibidores de cox
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
BR112015014367A2 (pt) formulações inibidoras de lfa-1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: MPJ OTC AB (SE)

B25D Requested change of name of applicant approved

Owner name: ADVANTICE HEALTH AB (SE)